Dataset Information

Synthesis of lipids for development of multifunctional lipid-based drug-carriers.

ABSTRACT: A simple approach to synthesize phospholipids to modulate drug release and track lipid-based particulate drug-carriers is described. We synthesized two ether lipids, 1 1-O-hexadecyl-2-pentadenoyl-sn-glycerol-3-phosphocholine (C(31)PC) and 2 1-O-hexadecyl-2-pentadenoyl-sn-glycerol-3-phosphomethanol (C(31)PM), and examined their ability to alter enzymatically triggered release of 6-carboxyfluorescein from liposomes incubated in TRIS buffer or fetal bovine serum solutions. Further, we demonstrated that odd-chain lipids, for example, C(31)PC, could be identified in rat plasma without interference of endogenous lipids. This approach can be adapted to synthesize a variety of lipids for use in developing and optimizing multifunctional drug-carriers.

SUBMITTER: Zhu G

PROVIDER: S-EPMC3195505 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Synthesis of lipids for development of multifunctional lipid-based drug-carriers.

Zhu Guodong G Alhamhoom Yahya Y Cummings Brian S BS Arnold Robert D RD

Bioorganic & medicinal chemistry letters 20110908 21

A simple approach to synthesize phospholipids to modulate drug release and track lipid-based particulate drug-carriers is described. We synthesized two ether lipids, 1 1-O-hexadecyl-2-pentadenoyl-sn-glycerol-3-phosphocholine (C(31)PC) and 2 1-O-hexadecyl-2-pentadenoyl-sn-glycerol-3-phosphomethanol (C(31)PM), and examined their ability to alter enzymatically triggered release of 6-carboxyfluorescein from liposomes incubated in TRIS buffer or fetal bovine serum solutions. Further, we demonstrated ...[more]

PMID: 21955941

Similar Datasets

Project description:In recent years, various nanotechnology platforms in the area of medical biology, including both diagnostics and therapy, have gained remarkable attention. Moreover, research and development of engineered multifunctional nanoparticles as pharmaceutical drug carriers have spurred exponential growth in applications to medicine in the last decade. Design principles of these nanoparticles, including nanoemulsions, dendrimers, nano-gold, liposomes, drug-carrier conjugates, antibody-drug complexes, and magnetic nanoparticles, are primarily based on unique assemblies of synthetic, natural, or biological components, including but not limited to synthetic polymers, metal ions, oils, and lipids as their building blocks. However, the potential success of these particles in the clinic relies on consideration of important parameters such as nanoparticle fabrication strategies, their physical properties, drug loading efficiencies, drug release potential, and, most importantly, minimum toxicity of the carrier itself. Among these, lipid-based nanoparticles bear the advantage of being the least toxic for in vivo applications, and significant progress has been made in the area of DNA/RNA and drug delivery using lipid-based nanoassemblies. In this review, we will primarily focus on the recent advances and updates on lipid-based nanoparticles for their projected applications in drug delivery. We begin with a review of current activities in the field of liposomes (the so-called honorary nanoparticles), and challenging issues of targeting and triggering will be discussed in detail. We will further describe nanoparticles derived from a novel class of amphipathic lipids called bolaamphiphiles with unique lipid assembly features that have been recently examined as drug/DNA delivery vehicles. Finally, an overview of an emerging novel class of particles (based on lipid components other than phospholipids), solid lipid nanoparticles and nanostructured lipid carriers will be presented. We conclude with a few examples of clinically successful formulations of currently available lipid-based nanoparticles.

Dataset Information

Synthesis of lipids for development of multifunctional lipid-based drug-carriers.

Publications

Synthesis of lipids for development of multifunctional lipid-based drug-carriers.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets